XOMA Royalty Corporation (XOMA)
NASDAQ: XOMA · Real-Time Price · USD
20.33
-0.64 (-3.05%)
Mar 28, 2025, 4:00 PM EDT - Market closed
XOMA Royalty Revenue
In the year 2024, XOMA Royalty had annual revenue of $28.49M with 498.72% growth. XOMA Royalty had revenue of $8.71M in the quarter ending December 31, 2024, with 375.40% growth.
Revenue (ttm)
$28.49M
Revenue Growth
+498.72%
P/S Ratio
8.35
Revenue / Employee
$2,191,308
Employees
13
Market Cap
243.53M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 28.49M | 23.73M | 498.72% |
Dec 31, 2023 | 4.76M | -1.27M | -21.06% |
Dec 31, 2022 | 6.03M | -32.13M | -84.21% |
Dec 31, 2021 | 38.16M | 8.78M | 29.86% |
Dec 31, 2020 | 29.39M | 11.02M | 59.96% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
XOMA News
- 9 days ago - XOMA Royalty Declares Quarterly Preferred Stock Dividends - GlobeNewsWire
- 11 days ago - XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements - GlobeNewsWire
- 4 weeks ago - Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences - GlobeNewsWire
- 4 weeks ago - XOMA Royalty to Present at Investor Conferences in March - GlobeNewsWire
- 7 weeks ago - XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 5 months ago - XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities - GlobeNewsWire
- 5 months ago - XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience - GlobeNewsWire
- 5 months ago - Twist Bioscience Enters into Royalty Purchase Agreement with XOMA Royalty for $15 Million in Cash - Business Wire